



Contemporary Approaches and Considerations of Cardioversion for Arrhythmia Reversal

Marc Glineur*

Department of Cardiac Surgery, University of Ottawa, Ontario, Canada

DESCRIPTION

Cardioversion, a medical therapy, is used to correct specific arrhythmic heart rhythms in patients and return their hearts to normal rhythm. Cardioversion tries to reset the heart's electrical impulses and return it to its normal rhythm by giving it a perfectly timed electrical shock [1].

Identifying arrhythmias

Electrical impulses that regulate the heart's chamber contractions govern the heart's regular beat. Arrhythmias, or irregular heartbeats, can develop as a result of a number of circumstances, including ageing, cardiac disease, and some medications. Atrial fibrillation, atrial flutter, and ventricular tachycardia are a few examples of typical arrhythmias [2].

Purpose of cardioversion

Cardioversion helps to stop the erratic electrical activity and re-establish a regular sinus rhythm so that the heart's natural pacemaker can take over. Two different types of arrhythmias are most commonly treated with cardioversion:

Atrial Fibrillation (AF): In the top chambers of the heart (the atria), atrial fibrillation is a frequent arrhythmia characterised by fast and erratic electrical impulses. Because of the poor blood flow caused by this erratic rhythm, the risk of blood clots and stroke is elevated [3].

Atrial flutter: Atrial flutter and atrial fibrillation both include erratic electrical activity in the atria, although flutter is more organised and fast [4].

Types of cardioversion

Cardioversion comes in two primary varieties:

Electrical cardioversion: Cardioversion with electrical energy is accomplished by administering a regulated electrical shock to the heart via the chest wall. The shock is set to happen at a certain cycle, in rhythm with the patient's heartbeat. To reduce pain, this treatment is often carried out under sedation or general anesthesia [5].

Chemical cardioversion: To return the heart's rhythm to normal, chemical cardioversion uses pharmaceuticals such as antiarrhythmic. This method, unlike electrical cardioversion, depends on the medications' capacity to maintain the electrical activity of the heart rather than administering a shock [6-7].

The cardioversion procedure

To determine the kind of arrhythmia and evaluate general heart health, the patient is subjected to a complete medical evaluation that includes a physical examination, Electrocardiogram (ECG), and other cardiac testing. Blood thinners may be recommended to individuals with atrial fibrillation or atrial flutter to lower the risk of blood clots, particularly if the arrhythmia has been present for a long time [8].

In order to lower the risk of aspiration during sedation or anesthesia, the patient is frequently urged to fast for a few hours prior to the treatment.

Electrodes are positioned on the patient's chest to administer the shock during electrical cardioversion. To guarantee exact timing of the electrical impulse, additional monitoring electrodes may be positioned on the arms and legs.

To reduce any discomfort during electrical cardioversion, patients are given sedative or general anesthetic. The healthcare professional administers the synchronized electrical shock after the patient has received sufficient sedation or anesthesia.

The shock aids in resetting the electrical activity of the heart and establishing a healthy sinus rhythm. Patients are routinely watched after cardioversion to gauge the heart's reaction and recuperation. To guarantee a speedy recovery, the medical staffs continue to keep an eye on the patient's vital signs, heart rhythm, and general health [9].

Considerations and potential complications

Cardioversion is often regarded as a secure and reliable method for re-establishing a healthy cardiac rhythm. However, the following elements and potential issues need to be taken into account:

Correspondence to: Marc Glineur, Department of Cardiac Surgery, University of Ottawa, Ontario, Canada, E-mail: mglineur@ottawaheart.ca

Received: 03-Jul-2023, Manuscript No. CPO-23-22500; **Editor assigned:** 05-Jul-2023, Pre QC No. CPO-23-22500 (PQ); **Reviewed:** 19-Jul-2023, QC No. CPO-23-22500; **Revised:** 26-Jul-2023, Manuscript No. CPO-23-22500 (R); **Published:** 02-Aug-2023, DOI:10.35248/2329-6607.23.12.363

Citation: Glineur M (2023) Contemporary Approaches and Considerations of Cardioversion for Arrhythmia Reversal. *Cardiovasc Pharm.* 12:363.

Copyright: © 2023 Glineur M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Blood clot risk: Patients with atrial fibrillation or atrial flutter are at a high risk of developing blood clots, particularly if blood thinners have not been given or treated properly [10].

Arrhythmia recurrence: After cardioversion, arrhythmias may occasionally resurface. To stop recurrences, the medical staff may recommend medications or other treatments.

Sedation and anaesthesia: The use of sedation or anaesthetic has hazards associated with it, such as allergic responses or respiratory issues.

CONCLUSION

Atrial fibrillation and atrial flutter are two arrhythmias that can benefit from cardioversion as a treatment. Cardioversion seeks to re-establish a healthy cardiac rhythm and enhance blood flow by administering a properly timed electrical shock or by employing medicines. To achieve the greatest results from any medical operation, it is essential for patients to go through a complete examination, adhere to pre-surgery instructions, and get post-surgical care. Cardioversion is still a safe and useful weapon in the arsenal of healthcare professionals because to technological and medical advancements and it helps patients with arrhythmias live better lives and improve their cardiovascular health.

REFERENCES

1. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis: a major contributor to global disease burden. *Arterioscler Thromb Vasc Biol.* 2014;34(11):2363–2371.
2. Ding BS, Dziubla T, Shuvaev VV, Muro S, Muzykantov VR. Advanced drug delivery systems that target the vascular endothelium. *Mol Interv.* 2006;6(2):98.
3. Mackay JH, Powell SJ, Osgathorp J, Rozario CJ. Six-year prospective audit of chest reopening after cardiac arrest. *Eur J Cardiothorac Surg.* 2002;22(3):421-425.
4. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. *Circulation.* 2006;113:577–582.
5. Keeling WB, Sundt T, Leacche M. Outcomes after surgical pulmonary embolectomy for acute pulmonary embolus: A multi-institutional study. *Ann Thorac Surg.* 2016;102:1498-1502.
6. Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, et al. European society of cardiology: cardiovascular disease statistics 2017. *Eur Heart J.* 2018;4(1):1-3.
7. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. *Pharm Res.* 2016;33(10):2373-87.
8. Biarent D, Bingham R, Richmond S, Maconochie I, Wyllie J, Simpson S, et al. European Resuscitation Council guidelines for resuscitation: Section 6. Paediatric life support. *Resuscitation.* 2005; 67(1):S97-S133.
9. Dunning J, Fabbri A, Kolh PH. Guideline for resuscitation in cardiac arrest after cardiac surgery. *Eur J Cardiothorac Surg. Eur J Cardiothorac Surg.* 2009;36(1):3-28.
10. Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: multicenter Lombardy registry. *Circulation.* 2018;138(11):1088-99.